Werewolf Therapeutics, Inc.
HOWL
We are an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing th…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$28M
▲ +13.7% YoY
Op. Margin
–
ROIC
-40.52%
▼ -4.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$24M
▼ -6.8% YoY
Op. Cash Flow (TTM)
-$24M
▼ -7.3% YoY
Net Debt
-$42M
Net Cash Position
Cash & Equiv.
$42M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with HOWL
Werewolf Therapeutics (HOWL) in two numbers
Questions about Werewolf Therapeutics
Does Werewolf Therapeutics (HOWL) pay a dividend?
No. Werewolf Therapeutics (HOWL) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 9 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in HOWL's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing HOWL
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.